Broker Name: iFAST Financial Pte Ltd
Date of Report: 13 July 2026
Excerpt from iFAST Financial Pte Ltd report.
Report Summary
- Stock: UltraGreen.ai (SGX: ULG)
- Action: Initiate coverage with BUY recommendation
- Target Price: USD 1.86 (implies 46.2% upside from closing price of USD 1.27 as of 9 July 2026)
Key Investment Highlights:
- Market Leadership: UltraGreen.ai holds a near-monopoly position in the global Indocyanine Green (ICG) market, with approximately 68% global market share and dominant positions in both the US (83%) and Europe (94%).
- Recurring Revenue Model: Every fluorescence-guided surgery (FGS) requires a new ICG vial, creating highly predictable, recurring revenues tied to surgical volumes rather than equipment cycles.
- Strong Growth Drivers: Structural tailwinds include increased adoption of robotic and minimally invasive surgery, robust clinical evidence, and professional guidelines (notably the 2025 SAGES recommendation for ICG use).
- Geographic Expansion: The company is extending its global footprint into South/Southeast Asia and the Middle East, supported by new regulatory approvals and an asset-light distributor model.
- Financial Strength: Debt-free balance sheet with USD 176.1 million net cash; industry-leading gross margin of 84.9% in 2025.
- Valuation: Target price set at USD 1.86 based on a 20x forward P/E multiple of 2028E earnings, reflecting the company’s dominant market position, visible growth runway, and strong recurring earnings profile.
- Risks: Revenue is concentrated in the US market; reliance on third-party manufacturing and supply chain; founder controls 61.9% of shares, raising governance considerations.
Actionable Insight: Investors are advised to consider initiating or increasing exposure to UltraGreen.ai (SGX: ULG) at current levels, given the substantial upside potential to the target price and the company’s structural advantages in a rapidly growing medical technology segment.
Above is an excerpt from a report by iFAST Financial Pte Ltd. Clients of iFAST Financial Pte Ltd can access the full research report from the broker’s website: iFAST Financial Pte Ltd research website.
